Results 131 to 140 of about 2,118,431 (433)

A prospective adaptive utility trial to validate performance of a novel urine exosome gene expression assay to predict high-grade prostate cancer in patients with prostate-specific antigen 2-10ng/ml at initial biopsy [PDF]

, 2018
BACKGROUND: Discriminating indolent from clinically significant prostate cancer (PCa) in the initial biopsy setting remains an important issue. Prospectively evaluated diagnostic assays are necessary to ensure efficacy and clinical adoption.
Andriole, Gerry, Brown, Gordon, Carroll, Peter, Carter, Ballentine, Donovan, Michael J, Margolis, Eric, McKiernan, James, Noerholm, Mikkel, Partin, Alan, Shore, Neal, Skog, Johan, Thompson, Ian, Torkler, Phillipp   +12 more
core   +1 more source

Teaching percutaneous renal biopsy using unfixed human cadavers [PDF]

, 2015
Background: Percutaneous renal biopsy (PRB) is an important diagnostic procedure. Despite advances in its safety profile there remains a small but significant risk of bleeding complications.
Ali, Khalid A., Geddes, Colin, Mackinnon, Bruce, Oliver, Scott W., Patel, Rajan K.   +4 more
core   +2 more sources

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

Molecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia, Anouk C. de Jong, Lisanne F. van Dessel, Vanja de Weerd, Corine Beaufort, Jean Helmijr, José Alberto Nakauma‐González, Job van Riet, Paul Hamberg, Daniel Vis, Michiel S. van der Heijden, Nick Beije, Martijn P. Lolkema, Teoman Deger, Saskia M. Wilting, Ronald de Wit, Maurice P. H. M. Jansen, John W. M. Martens   +17 more
wiley   +1 more source

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). [PDF]

, 2019
BackgroundFor men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer.
Bianchi-Frias, Daniella, Brooks, James D, Brown, Marshall D, Carroll, Peter R, Cooperberg, Matthew R, Dash, Atreya, Fabrizio, Michael D, Faino, Anna V, Gleave, Martin E, Lin, Daniel W, Liss, Michael, Morgan, Todd M, Nelson, Peter S, Newcomb, Lisa F, Thompson, Ian M, Wagner, Andrew A, Zheng, Yingye   +16 more
core  

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer. [PDF]

, 2015
The advances in targeted therapies for lung cancer are based on the evaluation of specific gene mutations especially the epidermal growth factor receptor (EGFR).
Huang, Wei-Lun, Lin, Chien-Chung, Su, Wu-Chou, Wei, Fang, Wong, David T   +4 more
core   +2 more sources

Integration of single‐cell and bulk RNA‐sequencing data reveals the prognostic potential of epithelial gene markers for prostate cancer

Molecular Oncology, EarlyView.
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley   +1 more source

Single-Cell Transcriptomics of a Human Kidney Allograft Biopsy Specimen Defines a Diverse Inflammatory Response.

Journal of the American Society of Nephrology, 2018
Background Single-cell genomics techniques are revolutionizing our ability to characterize complex tissues. By contrast, the techniques used to analyze renal biopsy specimens have changed little over several decades.
Haojia Wu, Andrew F. Malone, Erinn L. Donnelly, Y. Kirita, Kohei Uchimura, S. M. Ramakrishnan, J. Gaut, B. Humphreys   +7 more
semanticscholar   +1 more source

Response to neoadjuvant chemotherapy in early breast cancers is associated with epithelial–mesenchymal transition and tumor‐infiltrating lymphocytes

Molecular Oncology, EarlyView.
Epithelial–mesenchymal transition (EMT) and tumor‐infiltrating lymphocytes (TILs) are associated with early breast cancer response to neoadjuvant chemotherapy (NAC). This study evaluated EMT and TIL shifts, with immunofluorescence and RNA sequencing, at diagnosis and in residual tumors as potential biomarkers associated with treatment response.
Françoise Derouane, Jérôme Ambroise, Cédric van Marcke, Mieke Van Bockstal, Martine Berlière, Christine Galant, Hélène Dano, Médina Lougué, Elena Benidovskaya, Guy Jerusalem, Vincent Bours, Claire Josse, Jérôme Thiry, Aurélie Daumerie, Caroline Bouzin, Cyril Corbet, François P. Duhoux   +16 more
wiley   +1 more source

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients

Journal of Translational Medicine, 2018
Background The use of circulating tumor cells (CTCs) as indicators of treatment response in metastatic colorectal cancer (mCRC) needs to be clarified.
Mayte Delgado-Ureña, Francisco G. Ortega, Diego de Miguel-Pérez, Alba Rodriguez-Martínez, Jose L. García-Puche, Hugh Ilyine, Jose A. Lorente, Jose Exposito-Hernandez, M. Carmen Garrido-Navas, Miguel Delgado-Ramirez, M. José Serrano   +10 more
doaj   +1 more source

Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis

World Journal of Surgical Oncology, 2019
BackgroundBecause conventional prostate biopsy has some limitations, optimal variations of prostate biopsy strategies have emerged to improve the diagnosis rate of prostate cancer.
Jianjian Xiang, Huaqing Yan, Jiangfeng Li, Xiao Wang, Hong Chen, Xiangyi Zheng   +5 more
semanticscholar   +1 more source